286 related articles for article (PubMed ID: 14668879)
1. In search of the élite.
Gewin V
Nature; 2003 Dec; 426(6967):713-7. PubMed ID: 14668879
[No Abstract] [Full Text] [Related]
2. Best of both worlds.
Smaglik P
Nature; 2003 Dec; 426(6967):706-7. PubMed ID: 14668875
[No Abstract] [Full Text] [Related]
3. Finnish biotechnology--built on solid foundations.
Lähteenmäki R
Nature; 2002 Dec; 420(6916 Suppl):A34-5, A37, A39. PubMed ID: 12501125
[No Abstract] [Full Text] [Related]
4. Different directions?
Bowman L
Nature; 2003 Dec; 426(6967):712. PubMed ID: 14668878
[No Abstract] [Full Text] [Related]
5. Genzyme deal set to alter biotech landscape.
Ledford H
Nature; 2011 Feb; 470(7335):449. PubMed ID: 21350458
[No Abstract] [Full Text] [Related]
6. Biotechnology partnerships--medicine for an ailing industry?
DeLamarter J
Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
[No Abstract] [Full Text] [Related]
7. Biotechnology in the Medicon Valley.
Frank L
Nature; 2002 Dec; 420(6916 Suppl):A27, A29, A31 passim. PubMed ID: 12501124
[No Abstract] [Full Text] [Related]
8. Anthony Coyle.
Coyle A
Nat Biotechnol; 2011 Mar; 29(3):187. PubMed ID: 21390006
[No Abstract] [Full Text] [Related]
9. Elias Zerhouni.
Zerhouni E
Nat Biotechnol; 2011 Mar; 29(3):188. PubMed ID: 21390007
[No Abstract] [Full Text] [Related]
10. Back to basics: from industry to academia.
Powell K
Nature; 2004 Aug; 430(7000):706-7. PubMed ID: 15295606
[No Abstract] [Full Text] [Related]
11. Niche indications could drive higher valuations.
Ransom J
Nat Biotechnol; 2006 Dec; 24(12):1457. PubMed ID: 17160028
[No Abstract] [Full Text] [Related]
12. The biotechnology sector's craving for commercial expertise is fuelling a cultural exchange with drug industry.
Smaglik P; Frantz S
Nature; 2003 Apr; 422(6931):542-3. PubMed ID: 12673255
[No Abstract] [Full Text] [Related]
13. On the road to California.
DeWitt N
Nature; 2002 Dec; 420(6916 Suppl):A9. PubMed ID: 12510695
[No Abstract] [Full Text] [Related]
14. Biotechs hold their own in shifting industry.
Mitchell P
Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
[No Abstract] [Full Text] [Related]
15. Corporate venture capital and Cambridge.
McCammon MG; Pio E; Barakat S; Vyakarnam S
Nat Biotechnol; 2014 Oct; 32(10):975-8. PubMed ID: 25299912
[No Abstract] [Full Text] [Related]
16. Stuck in the middle.
Fuyuno I
Nature; 2006 Jul; 442(7100):237. PubMed ID: 16855561
[No Abstract] [Full Text] [Related]
17. Roche vows to keep Genentech culture.
Hayden EC
Nature; 2009 Mar; 458(7236):270. PubMed ID: 19295574
[No Abstract] [Full Text] [Related]
18. Fourth-quarter biotech job picture.
Francisco M
Nat Biotechnol; 2011 Feb; 29(2):169. PubMed ID: 21301443
[No Abstract] [Full Text] [Related]
19. Does biotech M&A benefit investors?
Jacobs T
Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
[No Abstract] [Full Text] [Related]
20. Is Elan a turnaround?
Jacobs T
Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
